ESTRO 2024 - Abstract Book

S1367

Clinical - Head & neck

ESTRO 2024

Conclusion:

Combining concurrent CHT with definitive RT does not lead to improved oncological outcomes for stage II NPC patients, even in the presence of lymphatic metastasis. Although the number of patients with lymph node metastasis is higher in the CRT group, the presence of limited lymph node metastasis has not been found to have any impact on survival rates. The decision to omit concurrent CHT may offer benefits in terms of reducing treatment-related toxicity without compromising oncological outcomes. However, further investigations are essential to identify the specific subgroups that may derive the maximum benefit from concurrent CHT for patients with Stage II NPC.

Keywords: Nasopharyngeal cancer, chemoradiotherapy

2031

Mini-Oral

Multivariable analysis of mandibular osteoradionecrosis predictors: results from the PREDMORN study

Laia Humbert Vidan 1,2,3 , Christian R Hansen 4 , Lisanne V van Dijk 5 , Clifton D Fuller 3 , Wilma Heemsbergen 6 , Carles Muñoz-Montplet 7,8 , Vinod Patel 9 , Steven Petit 6 , Gerda M Verduijn 6 , Arjen van der Schaaf 5 , Max J H Witjes 5 , Jordi Marruecos Querol 10 , Abdallah S R Mohamed 3 , Amy C Moreno 3 , Abdul A Khan 11 , Irene Oliveras Cancio 10 , Langendijk Hans 5 , Andrew P King 12 , Jørgen Johansen 13 , Teresa Guerrero Urbano 14 1 Guy's and St Thomas' NHS Foundation Trust, Department of Medical Physics, London, United Kingdom. 2 King's College London, School of Cancer and Pharmaceutical Sciences, London, United Kingdom. 3 The University of Texas MD Anderson Cancer Centre, Department of Radiation Oncology, Houston, USA. 4 University of Southern Denmark, Department of Clinical Research, Odense, Denmark. 5 University Medical Centre Groningen, Department of Radiation Oncology, Groningen, Netherlands. 6 Erasmus MC Cancer Institute, Department of Radiotherapy, Rotterdam, Netherlands. 7 Catalan Institute of Oncology, Department of Medical Physics and Radiation Protection, Girona, Spain. 8 University of Girona, Department of Medical Sciences, Girona, Spain. 9 Guy's and St Thomas' NHS Foundation Trust, Department of Oral Surgery, London, United Kingdom. 10 Catalan Institute of Oncology, Department of Radiation Oncology, Girona, Spain. 11 Odense University Hospital, Department of Oral and Maxillofacial Surgery, Odense, Denmark. 12 King's College London, School of Biomedical Engineering and Imaging Sciences, London, United Kingdom. 13 Odense University Hospital, Department of Oncology, Odense, Denmark. 14 Guy's and St Thomas' NHS Foundation Trust, Department of Clinical Oncology, London, United Kingdom

Purpose/Objective:

Osteoradionecrosis of the mandible (MORN) is a rare but severe side effect that develops in patients treated with radiotherapy for head and neck cancer (HNC). Due to its low prevalence rate, low patient numbers represent a statistical limitation in existing single-institution studies.